PERTH, Australia – The majority of medical device and biopharma industry respondents agreed that Australia’s Therapeutic Goods Administration (TGA) responded effectively to COVID-19, but they want to see the agency improve its processes to act faster and with more clarity, according to the TGA’s annual stakeholder survey.
From nearly every angle, med-tech financings in 2020 are at a four-year high, raising the industry a whopping $59.7 billion, a 47% increase over the prior year. The records were set despite the deadly SARS-CoV-2 virus that shut down global economies throughout 10 months of the most disruptive year in a lifetime. The pandemic highlighted a widespread need for med-tech technologies, such as diagnostics, for which the industry delivered hundreds of options. Likewise, ventilators, personal protective equipment, telemedicine capabilities and wearables were in high demand.
The volume of med-tech deals and M&As in 2020 reached impressive levels, well above 2019, primarily due to the demands of a global pandemic, although the disclosed values of those alliances fell dramatically short. Even so, the spotlight that shined on digital health and diagnostics throughout the challenging year has potentially set up the med-tech industry for an influx of attention going forward.